In the KATE2 study comparing T-DM1 plus atezolizumab versus T-DM1 plus placebo in patients with HER2+ advanced breast cancer previously treated with a taxane and trastuzumab (and 48% also received pertuzumab), the median PFS in the control group was 6.8 months26. Here, ERBB2 is linked to breast carcinoma.